Abstract
This chapter presents the liquid chromatography tandem mass spectrometry-based metabolite identification strategies in pharmaceutical research. The assessment of the metabolic fate of drug candidates, knowledge of the routes of metabolism in animals and humans, and evaluation of the biological properties of metabolites represent important objectives in contemporary pharmaceutical research. Metabolite identification investigations are imperative to support various phases of pharmaceutical research, that is, drug discovery, preclinical development, and clinical development. The objectives of metabolite identification in early preclinical studies require higher throughput analytical approaches to support medicinal chemistry efforts in designing superior drug-like molecules. An early assessment of metabolic pathways provides valuable information in the context of drug discovery efforts, in which metabolic “soft spots” that lead to high clearance may be recognized promptly. The knowledge of biotransformation pathways is essential to the design of metabolically stable leads with acceptable pharmacokinetic characteristics. Several literature reviews have highlighted the successful design of new chemical entities (NCEs) with improved pharmacokinetic properties based on available drug metabolism information.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call